Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide plus ATRA with or without conventional chemotherapy for newly diagnosed acute promyelocytic leukemia
ChiCTR-IPR-15006821Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of arsenic trioxide and tretinoin in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Event-free survival rate, Hematological complete remission rate and 5 more. Started Jul 2015; status: recruiting.
02
Drugs
arsenic trioxidetretinoin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR-IPR-15006821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006821.